Seeing a company hit a 52-week low can make investors nervous. But in many cases, those moments can create opportunities rather than warnings.
Here are three ASX 200 shares currently trading near their lows that I think could be worth considering following this month's market selloff.
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL has had a tough period by its own very high standards.
The biotechnology giant has faced investor concerns around the underperformance of the key CSL Behring business and a surprise CEO transition that unsettled the market. Those factors have contributed to a significant pullback in the share price.
However, when I step back and look at the business, I still see one of the highest-quality healthcare companies listed on the ASX.
CSL's plasma therapies remain critical treatments used around the world, and global demand for these products continues to grow over time. The company also has a strong pipeline of new therapies and vaccines that could support future growth.
With the share price well below its previous highs, I think the risk-reward looks more balanced than it has for some time.
Temple & Webster Group Ltd (ASX: TPW)
Temple & Webster has also fallen to a 52-week low this week during the market selloff.
What stands out to me about Temple & Webster is how the business has grown over the past few years. The company operates an asset-light online model that allows it to scale efficiently while avoiding many of the costs faced by traditional furniture retailers. Its large product range, strong brand recognition, and data-driven merchandising approach have helped it build a leading position in online furniture sales in Australia.
While the market may be focusing on short-term consumer spending trends, I still believe the long-term shift toward online retail works in Temple & Webster's favour.
If the company continues to execute well, the current share price weakness could prove temporary.
Sigma Healthcare Ltd (ASX: SIG)
Sigma Healthcare is another ASX 200 company whose share price has been under pressure.
However, the company's merger with Chemist Warehouse has transformed its long-term outlook in my view.
The combination creates a vertically integrated pharmacy and wholesale group with significant scale across the Australian healthcare market. Chemist Warehouse is one of the most recognisable pharmacy brands in the country, and its retail network adds a powerful growth engine to Sigma's distribution platform.
Over time, I think the combined business has the potential to generate stronger earnings growth and improved efficiency through scale.
Sigma's current share price weakness could offer a compelling opportunity, in my opinion.
Foolish takeaway
A 52-week low doesn't always mean something is broken. Sometimes it simply reflects market weakness, short-term uncertainty, or shifting sentiment. When that happens, I like to look for companies where the long-term story still makes sense despite the recent weakness.
CSL, Temple & Webster, and Sigma Healthcare all stand out to me as businesses that could have brighter days ahead once market sentiment improves.
